Scientists investigate why COVID-19 hits older adults harder
NCT ID NCT04565067
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at blood samples from 83 adults in Maryland who have recovered from COVID-19. Researchers want to understand how specific immune cells called CD8 T cells respond to the virus and how this changes with age. The goal is to gather knowledge that could help create better vaccines for older adults.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help researchers design better COVID-19 vaccines that work well for older people.
- What could go wrong
- This is an early observational study with only 83 participants, so findings may not apply to everyone. It does not test any treatment or vaccine directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
83 people
The number who actually took part.
- Started
-
Sep 2020
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
COVID-19 recovered adult patients: sample size =100, both genders, 18 years of age and older, all races, and residents of the state of Maryland.
- Ages
-
18 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Ability of subject to understand the study and stated willingness to comply with all study procedures and availability for the duration of the study. 2. Male or female, aged 18 years or older. 3. Able to speak and read English. 4. Willingness and ability to come to the NIA Clinical Research Unit at MedStar Harbor Hospital in Baltimore for study procedures. 5. Proof of positive SARS-CoV-2 testing exhibiting no current clinical symptoms. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Unable to verify identification of volunteer by state issued ID card, driver's license, or military ID. Participants earning greater than $600.00/year are issued a 1099 form, therefore, positive identification is required. 2. Unable to provide informed consent 3. Current use of steroids, immunosuppressive medications, radiation therapy, or chemotherapy medications. 4. Pregnancy. 5. Received immunization therapy for COVID-19 or have received a COVID-19 vaccination prior to Visit 1. In addition, eligible participants may not be immediately able to participate in the study but might be eligible at a later date. These include: 1. Symptoms of a viral infection on visit 1 (defer until resolved). 2. Medication: Volunteers taking the following medications would be deferred for 2 weeks after course has been completed and volunteer is feeling well: Antibiotics, antifungals, antimalarials, antvirals. 3. Temporary steroids (tapers): Deferred for 72 hours after symptoms are resolved and prescription is completed if taken orally, intravenously, or intramuscular. No deferral if taken intranasal, inhaled, or for joint injection. 4. Infection or Fever: Deferred until 2 weeks after antibiotics are completed and /or volunteer is feeling well. 5. We wish to only select recovered confirmed COVID-19 patients. Therefore, those who may have a household member (co-habitant) who is newly diagnosed with COVID-19 or who has symptoms will be deferred for 14 days. 6. Treatment with another investigational drug or other intervention within 14 days of visit 1 per the discretion of the Principal Investigator.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institute of Aging, Clinical Research Unit
Baltimore, Maryland, 21224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does COVID-19 hide in the gut? scientists probe stool for clues
- Blood samples and health records could reveal why some COVID-19 cases turn severe
- Home antibody tests put to the test: can you read your own COVID-19 result?
- Can lung ultrasound reveal COVID-19's signature in the lungs?
- When the immune system Can't fight back: tracking three respiratory viruses
- The household maze: how does COVID-19 move between family members?